Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain

A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).

Inclusion Criteria:

• Moderate to severe pain attributed to knee osteoarthritis

Exclusion Criteria:

• Significant comorbidity
• Significant pain states other than osteoarthritis
• Concomitant medications that might affect assessments